872 results match your criteria Lupus Erythematosus Subacute Cutaneous


Are there distinct clinical and pathological features distinguishing Idiopathic from Drug-Induced Subacute Cutaneous Lupus Erythematosus? A European retrospective multicenter study.

J Am Acad Dermatol 2019 Feb 11. Epub 2019 Feb 11.

Dermatology - Department Medical Science and Public Health, University of Cagliari, Via Ospedale 54, 09124 Cagliari Italy; European Academy of Dermatology and Venereology (EADV) Task Force of Dermatopathology; SIDEMAST Dermatopathology Study Group of Italian Society of Dermatology.

Background: Clinical and pathological criteria to distinguish drug-induced subacute lupus erythematosus (DI-SCLE) from idiopathic (I-SCLE) are controversial.

Objective: Aim of the survey was a retrospective analysis of a consistent number of iatrogenous and idiopathic SCLE cases, by means of clinical and histopathological investigation.

Methods: Eleven European University Dermatology Units collected all diagnosed cases from January 2000 to December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.009DOI Listing
February 2019
1 Read
4.449 Impact Factor

Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.

Melanoma Res 2019 Feb 11. Epub 2019 Feb 11.

Departments of Dermatology.

Checkpoint blockade immunotherapy has revolutionized the treatment of advanced melanoma, with impressive survival benefits attained through upregulation of the anticancer immune response. Blockade of regulatory checkpoint molecules can, however, also result in aberrant immune activation leading to undesirable inflammation and autoimmunity. Although many genetic determinants have been described in patients with primary autoimmune diseases, it is uncertain whether patients developing autoimmune skin disease as an adverse effect of anti-PD-1 therapy share the same genetic risks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000587DOI Listing
February 2019

Dapsone: an old drug effective for subacute cutaneous lupus erythematosus.

Rheumatology (Oxford) 2019 Jan 4. Epub 2019 Jan 4.

Institute for Autoimmune Systemic and Neurological Diseases.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key434DOI Listing
January 2019
1 Read

When Chest Pain Reveals More: A Case of Hydrochlorothiazide-Induced Systemic Lupus Erythematosus.

Am J Case Rep 2019 Jan 7;20:26-30. Epub 2019 Jan 7.

Department of Internal Medicine, Trihealth Good Samaritan Hospital, Cincinnati, OH, USA.

BACKGROUND Drug induced lupus erythematosus is considered an autoimmune entity which is precipitated by medications. Hydrochlorothiazide has been recognized to cause subacute cutaneous lupus erythematosus, but very few cases of systemic drug induced lupus systemic erythematosus have been reported. CASE REPORT A 57-year-old Caucasian male with a past medical history of hypertension and hyperlipidemia presented with recurrent fevers, chest pain, and dyspnea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.911380DOI Listing
January 2019
2 Reads

Subacute cutaneous lupus erythematosus observed with ciprofloxacin.

BMJ Case Rep 2018 Dec 22;11(1). Epub 2018 Dec 22.

Dermatology Residency, Affiliated Dermatology, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-22770
Publisher Site
http://dx.doi.org/10.1136/bcr-2018-227707DOI Listing
December 2018
6 Reads

Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review.

Melanoma Res 2018 Nov 26. Epub 2018 Nov 26.

Departments of Dermatology.

Nivolumab is widely used to treat several late-stage malignancies such as melanoma and non-small-cell lung cancer by inhibiting the interaction between the programmed cell death protein-1 and its ligand. By stimulating an antitumor immune response, it also leads to immune adverse events. Here. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000536DOI Listing
November 2018
1 Read

Alopecias in lupus erythematosus.

Lupus Sci Med 2018 25;5(1):e000291. Epub 2018 Oct 25.

Corporal Michael J Crescenz VAMC, Philadelphia, Pennsylvania, USA.

Several patterns of hair loss can occur in lupus erythematosus (LE). Alopecias which show histological characteristics of LE are LE-specific, and include discoid LE (DLE), diffuse or patchy hair loss in acute LE, subacute cutaneous LE, and rarely tumid LE. Lupus hair in SLE is a poorly characterised entity and may be a form of telogen effluvium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/lupus-2018-000291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203010PMC
October 2018
4 Reads

Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection.

J Eur Acad Dermatol Venereol 2018 Nov 5. Epub 2018 Nov 5.

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jdv.15330
Publisher Site
http://dx.doi.org/10.1111/jdv.15330DOI Listing
November 2018
18 Reads

Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.

JAMA Dermatol 2018 Dec;154(12):1432-1440

Department of Rheumatology, University College London Hospital, University College London, London, United Kingdom.

Importance: Cutaneous lupus erythematosus (CLE) can be severe and treatment resistant. B-cell depletion therapy (BCDT) with rituximab is well recognized in organ involvement in systemic lupus erythematosus (SLE), but its efficacy in cutaneous manifestations is less well established.

Objective: To evaluate the outcomes of BCDT in CLE and its clinical subtypes in the setting of associated SLE. Read More

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2018.3793DOI Listing
December 2018
2 Reads

[When drugs induce cutaneous lupus erythematosus].

Ugeskr Laeger 2018 Oct;180(41)

Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is defined as an adverse reaction to continuous use of a culprit drug. The reaction resolves upon drug withdrawal. More than 50 drugs have been linked to DI-SCLE, and it is estimated, that around 20% of the SCLE cases are drug-induced. Read More

View Article

Download full-text PDF

Source
October 2018
4 Reads

Keratotic papules in an annular arrangement.

JAAD Case Rep 2018 Oct 29;4(9):851-853. Epub 2018 Sep 29.

University of Texas Health at San Antonio, San Antonio, Texas.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23525126183017
Publisher Site
http://dx.doi.org/10.1016/j.jdcr.2018.06.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168923PMC
October 2018
3 Reads

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.

Br J Dermatol 2018 Sep 23. Epub 2018 Sep 23.

Department of Dermatology, Duke University Medical Center, Durham, NC, U.S.A.

Programmed cell death 1 (PD-1) blockade has rapidly emerged as an effective therapy for a wide variety of metastatic malignancies. It has been associated with multiple immune-related adverse effects, including cutaneous eruptions. We describe two patients with clinical and histological findings that were consistent with subacute cutaneous lupus erythematosus (SCLE) after receiving PD-1 inhibitor therapy for metastatic lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17245DOI Listing
September 2018
3 Reads

Annular Lesions: Diagnosis and Treatment.

Am Fam Physician 2018 Sep;98(5):283-291

Thomas Jefferson University Hospital, Philadelphia, PA, USA.

Annular lesions can present in a variety of diseases. Knowledge of the physical appearance and history of presentation of these skin findings can help in the diagnosis. A pruritic, annular, erythematous patch that grows centrifugally should prompt evaluation for tinea corporis. Read More

View Article

Download full-text PDF

Source
September 2018
9 Reads

Usefulness of Pulsed Dye Laser in Cutaneous Lupus Erythematosus.

Actas Dermosifiliogr 2018 Sep 10. Epub 2018 Sep 10.

Departamento de Dermatología, Hospital Universitario Ramón y Cajal, Madrid, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2018.03.020DOI Listing
September 2018
2 Reads

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept.

JAAD Case Rep 2018 Aug 16;4(7):698-700. Epub 2018 Aug 16.

Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113658PMC
August 2018
2 Reads

Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study.

Biomed Res Int 2018 25;2018:3491798. Epub 2018 Jul 25.

Department of Dermatology, University of Rzeszow, Rzeszow, Poland.

Pruritus is an important symptom frequently accompanying various inflammatory skin conditions. Some recent data have indicated that it may also be associated with autoimmune connective tissue diseases, including systemic sclerosis and dermatomyositis; however, studies on the prevalence and clinical characteristics of pruritus in CLE are limited. We have performed a multinational, prospective, cross-sectional study in order to assess the prevalence and intensity of pruritus in adult patients suffering from various subtypes of CLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3491798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083500PMC
January 2019
26 Reads

Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus: report of a case and review of the literature.

Dermatol Online J 2018 05 15;24(5). Epub 2018 May 15.

Department of Dermatology, University of California San Diego, La Jolla, California.

Severe bullous eruptions in systemic lupus erythematosus (SLE) patients include bullous SLE, Rowell syndrome, toxic epidermal necrolysis (TEN), and TEN-like eruption of acute cutaneous lupus (TEN-like ACLE). TEN-like ACLE, a rare manifestation of SLE that closely mimics TEN, can be distinguished by characteristic clinical and laboratory findings. A 27-year-old man with SLE who developed TEN-like ACLE after initiating mycophenolate mofetil for active SLE is reported. Read More

View Article

Download full-text PDF

Source
May 2018
13 Reads

MicroRNA Expression Profiling Identifies miR-31 and miR-485-3p as Regulators in the Pathogenesis of Discoid Cutaneous Lupus.

J Invest Dermatol 2019 Jan 18;139(1):51-61. Epub 2018 Aug 18.

Department of Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.

Cutaneous lupus erythematosus is a common and disfiguring manifestation in systemic lupus erythematosus. Subacute cutaneous lupus erythematosus and discoid lupus erythematosus (DLE) are the most prevalent forms. Despite sharing histological similarities, clinically they differ in their course and prognosis, suggesting different pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2018.07.026DOI Listing
January 2019
5 Reads

Cutaneous lupus erythematosus: Reflecting on practice-changing observations over the past 50 years.

Authors:
Jeffrey P Callen

Clin Dermatol 2018 Jul - Aug;36(4):442-449. Epub 2018 Apr 10.

Division of Dermatology, University of Louisville School of Medicine, Louisville, Kentucky, USA. Electronic address:

Several historical observations have led to the current understanding of the diagnosis, evaluation, and management of patients with cutaneous lupus erythematosus. Seminal advances in the management of this disease include the development of a classification system for cutaneous lupus, the use of a validated scoring system to assess patient disease activity, and expansion of knowledge of the action spectrum of this disease; further, observations regarding certain medications as potential causes of subacute cutaneous lupus erythematosus, the risk of progression from "pure" cutaneous disease to systemic disease, and traditional versus newer therapies are reviewed with closer inspection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2018.04.002DOI Listing
December 2018
1 Read

James Neil Gilliam, MD-the career arc of a patient-oriented translational clinical investigation changemaker in rheumatologic skin disease.

Ann Transl Med 2018 Jun;6(11):217

Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA.

James Neil Gilliam, MD, was an American academic physician who was trained in internal medicine, dermatology, dermatopathology and rheumatology. This "quadruple-threat" profile of postgraduate medical training provided him with a rather unique perspective on genetically-complex, environmentally-impacted human autoimmune disorders such as lupus erythematosus (LE). Both the skin and vital internal organs can be damaged by LE autoimmunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.05.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035984PMC
June 2018
2 Reads

A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus.

J Autoimmun 2018 Sep 11;93:1-15. Epub 2018 Jul 11.

Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China. Electronic address:

Lupus erythematosus (LE) is an autoimmune disease with a broad clinical spectrum ranging from cutaneous lesions to severe systemic manifestations. The pathogenesis of the disease and the immunological mechanisms for the heterogeneities in lupus remain unclear. The LE-specific cutaneous manifestations are generally divided into three categories: acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE) and chronic cutaneous lupus erythematosus (CCLE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2018.07.007DOI Listing
September 2018
19 Reads
8.410 Impact Factor

Case of severe acute lupus myocarditis and multiple-organ failure.

BMJ Case Rep 2018 Jun 19;2018. Epub 2018 Jun 19.

Department of Medicine, Logan Hospital, Meadowbrook, Queensland, Australia.

We report a case of severe lupus myocarditis with rapid, acute deterioration to cardiogenic shock and multiorgan failure, highlighting the importance of early identification and treatment of acute presentations in patients with systemic lupus erythematosus. A 31-year-old woman with previously diagnosed subacute cutaneous lupus erythematosus initially presented with abdominal pain and frank per-rectal bleeding. She deteriorated rapidly with type 1 respiratory failure and acute kidney injury requiring dialysis secondary to acute cardiac failure with a prolonged intensive care unit admission, over a month. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-225085DOI Listing
June 2018
16 Reads

Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus.

J Eur Acad Dermatol Venereol 2018 Jun 20. Epub 2018 Jun 20.

Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy.

Background: Anti-nuclear antibodies (ANA), anti-extractable nuclear antigens (ENA) and anti-dsDNA antibodies are often associated with cutaneous lupus erythematosus (CLE), with variable frequency depending on skin subtype. However, specific data based on large case-series on the pathogenetic, diagnostic and prognostic meaning of such autoantibodies are still lacking.

Objective: To characterize the correlations between CLE subtypes as well as LE-non-specific skin lesions and their autoantibody pattern. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15147DOI Listing

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus.

An Bras Dermatol 2018 Jun;93(3):467-469

Departament of Dermatology and Radiotherapy, Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Botucatu, SP, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20187561DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001093PMC
June 2018
5 Reads

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus.

J Clin Rheumatol 2018 Jun 15. Epub 2018 Jun 15.

From the Division of Dermatology, Department of Internal Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background/objective: Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)-like lupus erythematosus is a hyperacute and life-threatening form of cutaneous lupus erythematosus. Because of its rarity, little is known about this entity. We aimed to evaluate the clinical characteristics, laboratory findings, systemic manifestations, treatments, and outcome of SJS/ TEN-like lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000830DOI Listing
June 2018
2 Reads

Drug-induced lupus erythematosus: an update on drugs and mechanisms.

Authors:
Ye He Amr H Sawalha

Curr Opin Rheumatol 2018 Sep;30(5):490-497

Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Purpose Of Review: Rapid introduction of newly developed drugs in the absence of clear understanding of the pathophysiologic mechanisms behind drug-induced lupus erythematosus (DILE) can sometimes make DILE difficult to recognize in clinical practice. The purpose of this review is to summarize drugs most recently reported to be involved in DILE and discuss the current landscape of diverse mechanisms involved.

Recent Findings: A large number of proton pump inhibitor (PPI)-induced subacute cutaneous lupus erythematosus cases have been reported, suggesting a shift over time in the spectrum of drugs implicated in DILE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000522DOI Listing
September 2018
3 Reads

Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark.

Lupus 2018 Aug 22;27(9):1424-1430. Epub 2018 May 22.

2 OPEN - Open Patient data Explorative Network, Department of Clinical Research, University of Southern Denmark, Denmark.

Objectives The objectives of this paper are to describe the epidemiology of cutaneous lupus erythematosus (CLE) and its subtypes in Denmark, and to investigate the probability of receiving a subsequent diagnosis of systemic lupus erythematosus (SLE) and the related time course. Methods A nationwide registry-based cohort study was conducted in Denmark based on data from the Danish National Patient Registry from 1998 to 2013 using International Classification of Diseases, Revision 10. Results We identified 2380 patients with CLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318777103DOI Listing

Drug-induced Subacute Cutaneous Lupus Erythematosus Caused by a Topical Beta Blocker - Timolol.

Acta Dermatovenerol Croat 2018 Apr;26(1):44-47

Monika Bilewicz-Stebel, MD Department of Internal Medicine, Dermatology and Allergology, Curie-Skłodowskiej 10, 41-800 Zabrze, Poland, School of Public Health Medical University of Silesia in Katowice 40-027 Katowice, Poland;

Drug-induced lupus erythematosus (DI-LE) is an autoimmune condition secondary to a recent pharmacological intervention. There are no established specific diagnostic criteria for DI-LE, and the disease is recognized based on the medical history of the patient. Typically, the onset is closely related to a recent drug exposure, and the disease terminates after discontinuation of the inducing factor. Read More

View Article

Download full-text PDF

Source
April 2018
11 Reads

Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study.

Postepy Dermatol Alergol 2018 Apr 24;35(2):192-198. Epub 2018 Apr 24.

Department of Dermatology, University of Rzeszow, Rzeszow, Poland.

Introduction: Due to a wide array of dermatologic manifestations, assessment of disease severity in cutaneous lupus erythematosus (CLE) remains challenging. Given a need for some standardization in this field, we conducted a worldwide questionnaire-based study among physicians experienced in CLE management.

Aim: We asked about CLE assessment, their prophylactic measures advised to patients, and treatment recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2018.75242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949550PMC
April 2018
2 Reads

CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.

Arch Dermatol Res 2018 Aug 4;310(6):485-493. Epub 2018 May 4.

Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria.

Serum levels of the IFN-regulated cytokine CXCL13 have been found to correlate with SLEDAI and renal involvement in systemic lupus erythematosus. This study investigates whether CXCL13 can also be a marker of disease activity in patients with subacute cutaneous or chronic cutaneous lupus erythematosus (SCLE, CCLE). We analysed CXCL13 levels in 60 patients' sera (18 SLE, 19 SCLE, 23 CCLE) at five time points within 1 year and correlated these levels with disease activity scores and laboratory markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-018-1836-6DOI Listing
August 2018
5 Reads

Coexistence of chronic cutaneous lupus erythematosus and frontal fibrosing alopecia.

An Bras Dermatol 2018 Mar;93(2):274-276

Department of Dermatology, Universidade Federal de São Paulo, São Paulo, SP, Brazil.

Lupus erythemathosus is a chronic, relapsing disease with acute, subacute, and chronic lesions. Effluvium telogen occurs in the setting of systemic activity of the disease, and cicatricial alopecia results from discoid lesionsin on the scalp. Other types of alopecia, like alopecia areata, may rarely be found in lupus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20186992DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916406PMC
March 2018
5 Reads

Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.

Lupus 2018 Sep 10;27(10):1718-1722. Epub 2018 Apr 10.

1 Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces, Hospital Universitario Cruces, UPV/EHU Bizkaia, The Basque Country, Spain.

Aim The aim of this study was to evaluate the clinical response to combined therapy with hydroxychloroquine and mepacrine in patients with systemic lupus erythematosus and refractory joint and/or skin disease. Methods Mepacrine was added to 46 systemic lupus erythematosus patients unresponsive to treatment with the following drug combinations: hydroxychloroquine + prednisone + immunosuppressive drugs ( n = 24), hydroxychloroquine + prednisone ( n = 16), hydroxychloroquine + prednisone + retinoids ( n = 2), hydroxychloroquine alone ( n = 1), hydroxychloroquine + one immunosuppressive drug ( n = 1), hydroxychloroquine + prednisone + one immunosuppressive drug + belimumab ( n = 1) or hydroxychloroquine + prednisone + belimumab ( n = 1). The outcome variable was the clinical response, either complete or partial, based on clinical judgement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318768877DOI Listing
September 2018
3 Reads

The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda.

Lupus 2018 Jul 9;27(8):1383-1386. Epub 2018 Apr 9.

1 Division of Rheumatology, University of Michigan Medical School, USA.

A 29-year-old woman with a 1.5 year history of photosensitive skin lesions on her hands presented with a malar rash, bullous lesions on her hands, and was diagnosed with subacute lupus erythematosus after serologies revealed a positive antinuclear antibody test (1:2560), and antibodies to Ro/SSA and dsDNA. Hydroxychloroquine (400 mg/day) was prescribed and the patient developed severe drug-induced liver injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203318768884DOI Listing
July 2018
6 Reads

Occupational subacute cutaneous lupus erythematosus caused by outdoor work.

J Dtsch Dermatol Ges 2018 Apr 30;16(4):487-489. Epub 2018 Mar 30.

Department of Dermatology, University Hospital Jena, Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13478DOI Listing
April 2018
1 Read

Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent.

Pediatr Dermatol 2018 May 23;35(3):e189-e190. Epub 2018 Mar 23.

Department of Dermatology, University of Minnesota, Minneapolis, MN, USA.

Subacute cutaneous lupus erythematosus is rare in children. Most patients respond well to conventional therapy with prednisone, hydroxychloroquine, or both. Other case reports and small series have reported successful clearance with rituximab in adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13442DOI Listing
May 2018
10 Reads

Subacute cutaneous lupus erythematosus presenting in twins.

Pediatr Dermatol 2018 Mar 13;35(2):e128-e131. Epub 2018 Feb 13.

Division of Pediatric Dermatology, Department of Dermatology, College of Medicine, University of Florida, Gainesville, FL, USA.

Subacute cutaneous lupus erythematosus is a clinically distinct form of cutaneous lupus erythematosus, with age of onset typically in the second to fifth decades. Eleven cases have been reported in childhood, and we present the first known case of subacute cutaneous lupus erythematosus in identical twins. Although flares are typically photo-induced, we present an annular eruption typical of subacute cutaneous lupus erythematosus with concurrent pinworm infestation, with recurrence of disease with cutaneous larva migrans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13434DOI Listing
March 2018
2 Reads

Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report.

Exp Ther Med 2018 Jan 23;15(1):785-788. Epub 2017 Nov 23.

Department of Ophthalmology, Grigore T. Popa University of Medicine and Pharmacy, 700715 Iași, Romania.

Rowell syndrome is defined as the association between lupus erythematosus, erythema multiforme-like lesions and characteristic immunological changes including positive tests for rheumatoid factor, speckled antinuclear antibody, positive anti-Ro or anti-La antibodies. The present report presents the case of a 45-year-old female patient who was previously diagnosed in January 2010 with terbinafine-induced subacute cutaneous lupus erythematosus and was admitted for a skin eruption consisting of erythematous-papular erythema multiforme-like lesions, primarily on the trunk and limbs. The associated symptoms consisted of fatigability, myalgia and gonalgia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2017.5557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777104PMC
January 2018
17 Reads

Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea.

J Dermatol 2018 Apr 9;45(4):436-443. Epub 2018 Feb 9.

Department of Dermatology, College of Medicine, University of Hanyang, Seoul, Korea.

An understanding of the differences in clinical manifestations and laboratory abnormalities between subtypes of cutaneous lupus erythematosus (CLE) is still lacking. The purpose of this study was to analyze demographic, clinical and histological features of CLE according to three main presentation subsets: acute (ACLE), subacute (SCLE) and chronic (CCLE). A 10-year retrospective analysis was performed on data from patients who were diagnosed with CLE between March 2005 and September 2015 in a Korean tertiary referral dermatology clinic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14233DOI Listing
April 2018
2 Reads

The use of SLICC and ACR criteria to correctly label patients with cutaneous lupus and systemic lupus erythematosus.

Clin Rheumatol 2018 Mar 1;37(3):817-818. Epub 2018 Feb 1.

Dermatology Department, St. James's Hospital, Dublin, Ireland.

The American College of Rheumatology (ACR) classification criteria for lupus and Systemic Lupus International Collaborating Clinics (SLICC) criteria are designed to classify disease. However, they have become widely used as diagnostic criteria in clinical situations. Patients may be labelled as systemic lupus erythematosus (SLE) in their medical records, when in fact they have cutaneous lupus erythematosus (CLE) without systemic symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-3999-0DOI Listing
March 2018
3 Reads

Cutaneous lupus erythematosus: clinico-pathologic correlation.

G Ital Dermatol Venereol 2018 Apr 24;153(2):216-229. Epub 2018 Jan 24.

Unit of Dermatology, "A. Perrino" Hospital, Brindisi, Italy.

Cutaneous lupus erythematosus (CLE) is a chronic-relapsing disease. It is defined as a LE localized to the skin without any significant systemic symptoms. Its annual incidence is of 4 cases per 100,000 persons with a prevalence of 73 cases per 100,000 persons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.18.05929-1DOI Listing
April 2018
2 Reads

Subacute cutaneous lupus erythematosus: is clopidogrel a trigger?

Clin Exp Dermatol 2018 07 12;43(5):600-601. Epub 2018 Jan 12.

Department of Dermatology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, W2 1NY, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.13379DOI Listing
July 2018
6 Reads

Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib.

J Cutan Med Surg 2018 May/Jun;22(3):341-343. Epub 2018 Jan 6.

1 Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475417752369DOI Listing
December 2018
4 Reads

Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.

Acta Dermatovenerol Croat 2017 Oct;25(3):255-256

Sheng-Yiao Lin, No. 100, Tzyou 1st Road, Kaohsiung 807, Taiwan;

Dear Editor, Bullous pemphigoid (BP), a relatively common autoimmune blistering disease in the elderly, is characterized by large, tense bullae on urticarial, erythematous, or normal skin. However, atypical BP with polymorphic clinical presentations is rarely encountered, leading to misdiagnosis and delayed treatments (1). BP with lesions resembling erythema gyratum repens or figurate erythema has been regarded as a paraneoplastic phenomenon (1). Read More

View Article

Download full-text PDF

Source
October 2017
25 Reads

[Esomeprazol-induced cutaneous lupus erythematosus].

Z Gastroenterol 2017 Sep 12;55(9):861-865. Epub 2017 Sep 12.

Klinik für Gastroenterologie und gastrointestinale Onkologie, Georg-August-Universität Göttingen Universitätsmedizin, Göttingen, Germany.

Proton pump inhibitors are among the most commonly used drugs worldwide. They are considered to be largely safe and cause little side-effects. We report a 69-year-old woman who suffered from erythematous plaques 2 months after initiating therapy with esomeprazole. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0043-113833DOI Listing
September 2017
3 Reads

[Secukinumab-induced subacute-cutaneous lupus erythematosus].

Hautarzt 2018 Jan;69(1):64-66

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstr. 55, 45122, Essen, Deutschland.

We report about a 52-year-old woman with onset of drug-induced lupus erythematosus (DILE) in sun-exposed areas, under therapy with secukinumab. Topical therapy with a steroid class 3 for 4 weeks showed substantial improvement. The systemic therapy was switched to ustekinumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-017-4071-8DOI Listing
January 2018
3 Reads

Significant symptomatic improvement of subacute cutaneous lupus after testosterone therapy in a female-to-male transgender subject.

Lupus 2018 02 9;27(2):347-348. Epub 2017 Oct 9.

Department of Medicine-Division of Rheumatology, 1092 Albany Medical Center , Albany, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203317734921DOI Listing
February 2018

Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.

J Investig Dermatol Symp Proc 2017 10;18(2):S64-S68

Department of Dermatology, Virginia Commonwealth University, Richmond, Virginia, USA.

Systemic lupus erythematosus is a chronic inflammatory condition which affects predominantly women in their 30s. It has several clinical manifestations, including skin lesions that can be classified as acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus. A multifaceted approach to treating cutaneous lupus is advocated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jisp.2017.02.001DOI Listing
October 2017
3 Reads